# Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

> **NCT02372799** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 473 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vilazodone
- **DRUG:** Placebo
- **DRUG:** Fluoxetine

## Key facts

- **NCT ID:** NCT02372799
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-28
- **Primary completion:** 2018-09-11
- **Final completion:** 2018-09-11
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372799, "Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02372799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*